Eventide Asset Management - Q2 2015 holdings

$1.85 Billion is the total value of Eventide Asset Management's 110 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 17.1% .

 Value Shares↓ Weighting
CELG BuyCELGENE CORP$76,964,000
+251.4%
665,000
+250.0%
4.16%
+152.7%
BLUE  BLUEBIRD BIO INC$67,819,000
+39.4%
402,8000.0%3.67%
+0.3%
ABBV BuyABBVIE INC$52,697,000
+138.7%
784,300
+108.0%
2.85%
+71.6%
MIC BuyMACQUARIE INFRASTRUCTURE COR$52,363,000
+30.1%
633,700
+29.6%
2.83%
-6.4%
SUNEQ BuySUNEDISON INC$47,066,000
+63.4%
1,573,600
+31.1%
2.55%
+17.5%
RHT BuyRED HAT INC$44,123,000
+30.9%
581,100
+30.6%
2.39%
-5.9%
LOW BuyLOWES COS INC$43,222,000
+13.6%
645,400
+26.2%
2.34%
-18.3%
MBBYF BuyMOBILEYE N V AMSTELVEEN$40,898,000
+97.1%
769,200
+55.8%
2.21%
+41.7%
PANW BuyPALO ALTO NETWORKS INC$40,688,000
+35.5%
232,900
+13.3%
2.20%
-2.6%
FEYE BuyFIREEYE INC$40,512,000
+57.3%
828,300
+26.2%
2.19%
+13.1%
SPLK BuySPLUNK INC$39,600,000
+111.0%
568,800
+79.4%
2.14%
+51.7%
DATA BuyTABLEAU SOFTWARE INCcl a$39,594,000
+64.3%
343,400
+31.8%
2.14%
+18.1%
MGA BuyMAGNA INTL INC$39,543,000
+33.3%
705,000
+27.5%
2.14%
-4.1%
LRCX BuyLAM RESEARCH CORP$39,235,000
+59.2%
482,300
+37.4%
2.12%
+14.5%
XPO BuyXPO LOGISTICS INC$38,322,000
+35.2%
848,200
+36.1%
2.07%
-2.7%
LEA BuyLEAR CORP$36,743,000
+11.6%
327,300
+10.2%
1.99%
-19.7%
CCI BuyCROWN CASTLE INTL CORP NEW$36,520,000
+83.4%
454,800
+88.5%
1.98%
+31.8%
CYBR NewCYBERARK SOFTWARE LTD$35,807,000570,000
+100.0%
1.94%
KAR BuyKAR AUCTION SVCS INC$35,478,000
+27.9%
948,600
+29.7%
1.92%
-8.0%
DYAX  DYAX CORP$35,256,000
+58.2%
1,330,4000.0%1.91%
+13.8%
SYNA BuySYNAPTICS INC$33,870,000
+55.3%
390,500
+45.5%
1.83%
+11.7%
WAB BuyWABTEC CORP$32,984,000
+28.4%
350,000
+29.4%
1.78%
-7.7%
ASML BuyASML HOLDING N V$32,561,000
+30.0%
312,700
+26.1%
1.76%
-6.5%
WBC  WABCO HLDGS INC$31,623,000
+0.7%
255,6000.0%1.71%
-27.6%
PFPT BuyPROOFPOINT INC$31,383,000
+120.9%
492,900
+105.5%
1.70%
+58.8%
TSLA BuyTESLA MTRS INC$29,589,000
+93.5%
110,300
+36.2%
1.60%
+39.1%
EXR BuyEXTRA SPACE STORAGE INC$26,147,000
+67.6%
400,900
+73.6%
1.42%
+20.5%
STLD BuySTEEL DYNAMICS INC$25,105,000
+18.2%
1,211,900
+14.7%
1.36%
-15.1%
TRN  TRINITY INDS INC$24,133,000
-25.6%
913,1000.0%1.31%
-46.5%
FPRX BuyFIVE PRIME THERAPEUTICS INC$23,794,000
+24.1%
957,900
+14.1%
1.29%
-10.8%
MDVN  MEDIVATION INC$23,776,000
-11.5%
208,2000.0%1.29%
-36.4%
MGNX BuyMACROGENICS INC$23,636,000
+81.0%
622,500
+49.5%
1.28%
+30.1%
CBI BuyCHICAGO BRIDGE & IRON CO N V$23,429,000
+47.2%
468,200
+44.9%
1.27%
+5.8%
VCYT BuyVERACYTE INC$22,854,000
+106.9%
2,051,498
+35.2%
1.24%
+48.9%
CMRX BuyCHIMERIX INC$22,675,000
+35.3%
490,800
+10.4%
1.23%
-2.7%
IMPV NewIMPERVA INC$22,321,000329,700
+100.0%
1.21%
IDTI BuyINTEGRATED DEVICE TECHNOLOGY$22,303,000
+43.5%
1,027,800
+32.4%
1.21%
+3.3%
NVAX  NOVAVAX INC$21,263,000
+34.7%
1,908,7000.0%1.15%
-3.1%
BWA BuyBORGWARNER INC$20,809,000
+1.3%
366,100
+7.8%
1.13%
-27.1%
SCTY BuySOLARCITY CORP$19,963,000
+106.0%
372,800
+97.2%
1.08%
+48.1%
NRG BuyNRG ENERGY INC$19,588,000
-3.8%
856,100
+5.9%
1.06%
-30.8%
AGIO  AGIOS PHARMACEUTICALS INC$18,471,000
+17.9%
166,2000.0%1.00%
-15.3%
PTLA  PORTOLA PHARMACEUTICALS INC$18,461,000
+20.0%
405,3000.0%1.00%
-13.7%
IPHI  INPHI CORP$18,267,000
+28.2%
799,1000.0%0.99%
-7.8%
QLIK NewQLIK TECHNOLOGIES INC$18,225,000521,300
+100.0%
0.99%
CPN  CALPINE CORP$14,457,000
-21.3%
803,6000.0%0.78%
-43.5%
STKL BuySUNOPTA INC$13,844,000
+6.3%
1,290,200
+5.2%
0.75%
-23.6%
TTPH  TETRAPHASE PHARMACEUTICALS I$13,758,000
+29.5%
290,0000.0%0.74%
-7.0%
COLL NewCOLLEGIUM PHARMACEUTICAL INC$13,305,000745,802
+100.0%
0.72%
TEX BuyTEREX CORP NEW$12,960,000
+38.4%
557,400
+58.3%
0.70%
-0.6%
LLTC  LINEAR TECHNOLOGY CORP$12,942,000
-5.5%
292,6000.0%0.70%
-32.0%
EOG  EOG RES INC$12,677,000
-4.5%
144,8000.0%0.69%
-31.3%
LGND  LIGAND PHARMACEUTICALS INC$11,452,000
+30.9%
113,5000.0%0.62%
-5.9%
ACAD  ACADIA PHARMACEUTICALS INC$11,354,000
+28.5%
271,1000.0%0.61%
-7.7%
ININ  INTERACTIVE INTELLIGENCE GRO$9,881,000
+8.0%
222,2000.0%0.54%
-22.2%
CGNX BuyCOGNEX CORP$9,861,000
+10.5%
205,000
+13.9%
0.53%
-20.5%
AYR BuyAIRCASTLE LTD$9,716,000
+8.3%
428,600
+7.3%
0.53%
-22.1%
UFS  DOMTAR CORP$9,050,000
-10.4%
218,6000.0%0.49%
-35.5%
RARE BuyULTRAGENYX PHARMACEUTICAL IN$8,611,000
+101.0%
84,100
+21.9%
0.47%
+44.7%
STML BuySTEMLINE THERAPEUTICS INC$8,289,000
-7.6%
704,250
+13.6%
0.45%
-33.5%
SRPT  SAREPTA THERAPEUTICS INC$7,884,000
+129.1%
259,1000.0%0.43%
+64.9%
CLDX  CELLDEX THERAPEUTICS INC NEW$7,281,000
-9.5%
288,7000.0%0.39%
-34.9%
NBIX BuyNEUROCRINE BIOSCIENCES INC$7,231,000
+32.1%
151,400
+9.9%
0.39%
-5.1%
XNCR BuyXENCOR INC$7,200,000
+82.1%
327,700
+27.0%
0.39%
+30.9%
BMRN BuyBIOMARIN PHARMACEUTICAL INC$7,085,000
+41.8%
51,800
+29.2%
0.38%
+1.9%
TSRO BuyTESARO INC$6,784,000
+34.8%
115,400
+31.6%
0.37%
-3.2%
PWR  QUANTA SVCS INC$6,709,000
+1.0%
232,8000.0%0.36%
-27.4%
CMRE  COSTAMARE INC$6,617,000
+4.3%
360,2000.0%0.36%
-24.9%
ZSAN BuyZOSANO PHARMA CORP$6,368,000
-24.0%
878,400
+6.0%
0.34%
-45.3%
SGEN NewSEATTLE GENETICS INC$6,200,000128,100
+100.0%
0.34%
RTRX NewRETROPHIN INC$5,473,000165,100
+100.0%
0.30%
ALNY BuyALNYLAM PHARMACEUTICALS INC$5,454,000
+24.7%
45,500
+8.6%
0.30%
-10.3%
SGMO  SANGAMO BIOSCIENCES INC$5,351,000
-29.3%
482,5000.0%0.29%
-49.0%
CEMP  CEMPRA INC$5,285,000
+0.2%
153,8000.0%0.29%
-28.0%
SUPN  SUPERNUS PHARMACEUTICALS INC$4,866,000
+40.4%
286,6000.0%0.26%
+0.8%
DVAX BuyDYNAVAX TECHNOLOGIES CORP$4,556,000
+59.4%
194,500
+52.7%
0.25%
+14.9%
CERN BuyCERNER CORP$4,510,000
+2.4%
65,300
+8.7%
0.24%
-26.3%
CSLT NewCASTLIGHT HEALTH INCcl b$4,482,000550,600
+100.0%
0.24%
TGTX BuyTG THERAPEUTICS INC$4,498,000
+58.8%
271,100
+48.1%
0.24%
+14.1%
GWPH BuyGW PHARMACEUTICALS PLCads$4,435,000
+45.3%
36,100
+7.8%
0.24%
+4.3%
LOXO BuyLOXO ONCOLOGY INC$4,394,000
+207.9%
243,700
+112.7%
0.24%
+122.4%
RGEN  REPLIGEN CORP$4,102,000
+35.9%
99,4000.0%0.22%
-2.2%
DRNA BuyDICERNA PHARMACEUTICALS INC$3,840,000
+12.4%
275,300
+93.7%
0.21%
-19.1%
DBVT BuyDBV TECHNOLOGIES S Asponsored adr$3,824,000
+69.8%
128,400
+33.2%
0.21%
+22.5%
AZPN  ASPEN TECHNOLOGY INC$3,781,000
+18.3%
83,0000.0%0.20%
-14.6%
ATRC  ATRICURE INC$3,753,000
+20.2%
152,3000.0%0.20%
-13.6%
ESPR  ESPERION THERAPEUTICS INC NE$3,189,000
-11.7%
39,0000.0%0.17%
-36.4%
NTUS  NATUS MEDICAL INC DEL$3,192,000
+7.8%
75,0000.0%0.17%
-22.4%
AGTC  APPLIED GENETIC TECHNOL CORP$3,152,000
-23.3%
205,5000.0%0.17%
-44.7%
SAGE  SAGE THERAPEUTICS INC$2,935,000
+45.4%
40,2000.0%0.16%
+4.6%
XLRN  ACCELERON PHARMA INC$2,756,000
-16.9%
87,1000.0%0.15%
-40.2%
CSII BuyCARDIOVASCULAR SYS INC DEL$2,743,000
-18.3%
103,700
+20.6%
0.15%
-41.5%
ARAY  ACCURAY INC$2,457,000
-27.5%
364,6000.0%0.13%
-47.8%
QURE  UNIQURE NV$2,444,000
+11.0%
90,5000.0%0.13%
-20.5%
ONCE NewSPARK THERAPEUTICS INC$2,302,00038,200
+100.0%
0.12%
INSM  INSMED INC$2,164,000
+17.4%
88,6000.0%0.12%
-15.8%
IMDZ BuyIMMUNE DESIGN CORP$2,125,000
+22.8%
102,904
+25.6%
0.12%
-11.5%
OMED  ONCOMED PHARMACEUTICALS INC$1,915,000
-12.7%
85,1000.0%0.10%
-37.0%
ATHN  ATHENAHEALTH INC$1,868,000
-4.0%
16,3000.0%0.10%
-30.8%
RGLS BuyREGULUS THERAPEUTICS INC$1,759,000
-10.5%
160,516
+38.4%
0.10%
-35.8%
CDTX NewCIDARA THERAPEUTICS INC$1,719,000122,628
+100.0%
0.09%
TNDM BuyTANDEM DIABETES CARE INC$1,683,000
+2.8%
155,300
+19.7%
0.09%
-26.0%
SAAS SellINCONTACT INC$1,481,000
-29.7%
150,000
-22.4%
0.08%
-49.7%
INFI  INFINITY PHARMACEUTICALS INC$1,233,000
-21.7%
112,6000.0%0.07%
-43.2%
FEIC  FEI CO$1,227,000
+8.6%
14,8000.0%0.07%
-22.4%
MDSO  MEDIDATA SOLUTIONS INC$1,027,000
+10.8%
18,9000.0%0.06%
-20.0%
XOMA SellXOMA CORP DEL$591,000
-8.4%
152,200
-14.1%
0.03%
-34.7%
RPTP SellRAPTOR PHARMACEUTICAL CORP$253,000
-22.4%
16,000
-46.7%
0.01%
-44.0%
VSTM SellVERASTEM INC$82,000
-61.5%
10,900
-47.8%
0.00%
-75.0%
CDXS  CODEXIS INC$39,000
-15.2%
10,0000.0%0.00%
-33.3%
ZFGN ExitZAFGEN INC$0-600
-100.0%
-0.00%
TFX ExitTELEFLEX INC$0-5,800
-100.0%
-0.05%
PCRX ExitPACIRA PHARMACEUTICALS INC$0-13,300
-100.0%
-0.09%
AAVL ExitAVALANCHE BIOTECHNOLOGIES IN$0-37,400
-100.0%
-0.11%
FC ExitFRANKLIN COVEY CO$0-224,964
-100.0%
-0.33%
OII ExitOCEANEERING INTL INC$0-129,700
-100.0%
-0.53%
VMW ExitVMWARE INC$0-97,800
-100.0%
-0.60%
CXP ExitCOLUMBIA PPTY TR INC$0-393,800
-100.0%
-0.80%
NLNK ExitNEWLINK GENETICS CORP$0-215,700
-100.0%
-0.89%
SNDK ExitSANDISK CORP$0-321,800
-100.0%
-1.54%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2015-08-14
Signatures

The EDGAR filing(s) were signed by:

About Eventide Asset Management

Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.

The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.

The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.

Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.

Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
LOWES COS INC40Q3 20233.2%
PALO ALTO NETWORKS INC40Q3 20233.6%
ASML HOLDINGS NV40Q3 20231.9%
NEUROCRINE BIOSCIENCES INC40Q3 20231.1%
REPLIGEN CORP40Q3 20230.5%
VERACYTE INC38Q3 20231.5%
LAM RESEARCH CORP35Q3 20233.4%
XPO LOGISTICS INC34Q1 20233.8%
COLLEGIUM PHARMACEUTICAL INC34Q3 20232.6%
MAGNA INTL INC33Q4 20212.5%

View Eventide Asset Management's complete holdings history.

Latest significant ownerships (13-D/G)
Eventide Asset Management Q2 2015 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Cogent Biosciences, Inc.February 14, 20232,589,7783.7%
ESSA Pharma Inc.Sold outFebruary 14, 202300.0%
Freeline Therapeutics Holdings plcFebruary 14, 20235,920,7659.1%
KnowBe4, Inc.Sold outFebruary 14, 202300.0%
Praxis Precision Medicines, Inc.February 14, 20233,518,0627.5%
Prometheus Biosciences, Inc.February 14, 20231,032,9382.2%
SUTRO BIOPHARMA, INC.Sold outFebruary 14, 202300.0%
Vital Farms, Inc.Sold outFebruary 14, 202300.0%
Zymeworks Inc.Sold outFebruary 14, 202300.0%
Entasis Therapeutics Holdings Inc.February 14, 2022590,6021.2%

View Eventide Asset Management's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR/A2024-02-20
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Eventide Asset Management's complete filings history.

Compare quarters

Export Eventide Asset Management's holdings